Amber Tx acquires Bioinduction Limited and its Picostim DyNeuMo platform

Amber Therapeutics announces it has acquired Bioinduction Limited and its Picostim DyNeuMo neuromodulation therapy platform. Amber is using the platform to explore a closed-loop therapy for mixed urinary incontinence (Amber-UI). The acquisition supports the Company’s strategy to develop intelligent, transformative neuromodulation therapies for patients with functional disorders of the nervous system. Financial details are not disclosed.

Amber now occupies a unique position in the UK as a vertically integrated designer, developer and manufacturer of Class III Active implantable systems. In addition, the acquisition brings a highly skilled team with real-world experience developing and manufacturing neuromodulation devices for urinary incontinence, with more than 4,000 devices implanted to date through Finetech Medical, a subsidiary of Bioinduction. The integrated structure supports the Company’s accelerated effort to bring the Amber-UI therapy into a pivotal trial in the US, and eventually to end-market commercialisation globally.

The next-generation Picostim DyNeuMo platform is the implantable system used for delivering the Amber-UI therapy. The hardware is supported by a state-of-the-art, integrated data science toolkit for rapidly prototyping adaptive therapy algorithms. Amber-UI is currently progressing through a first-in-human study (AURA-2) with early indications confirming the safety and feasibility of the surgical procedure and adaptive therapy. The study is expected to conclude in early 2024.

The Picostim DyNeuMo system was originally developed as a cranial implant for delivering deep brain stimulation to treat patients with Parkinson’s disease. The system was further enhanced for closed-loop, adaptive therapies in partnership with a consortium of academic collaborators led by those at the University of Oxford and is currently in multiple first-in-human therapy trials.

Aidan Crawley, CEO of Amber, commented: “We are very excited to announce the acquisition of Bioinduction and its Picostim-DyNeuMo platform. Our teams worked together developing the platform from concept to first-in-human trials in under two years. This deal formally brings together an experienced group of professionals with decades of design, clinical and manufacturing experience, who can now focus on taking our first therapy to market.”

Tim Denison, Amber’s Chief Engineer, added: “The hardware, know-how and manufacturing experience that we gain with the acquisition of Bioinduction offers us the chance to accelerate the development and commercialisation of Amber-UI. The ability to rapidly prototype therapy innovations with our integrated research platform enables us to build a pipeline of novel neuromodulation therapies. In partnership with our academic ecosystem, we aim to develop cost-effective therapies for functional disorders of the nervous system, based on neuroscience, to address significant unmet needs.”
MB Bureau